Rexlemestrocel-l phase 3 trial results in chronic heart failure selected as late breaking presentation at american heart association annual meeting

New york, oct. 06, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that results from the randomized, controlled phase 3 trial of rexlemestrocel-l in 565 patients with new york heart association (nyha) class ii and class iii chronic heart failure (chf) with low ejection fraction (hfref) have been selected through peer review as a late breaking presentation at the american heart association (aha) annual meeting occurring november 13th- 15th. the featured session is titled ‘building on the foundations of treatment: advances in heart failure therapy'.
MESO Ratings Summary
MESO Quant Ranking